ReviewJournal of molecular and cellular cardiology2011
Pharmacologic and genetic strategies to enhance cell therapy for cardiac regeneration.
Review in Journal of molecular and cellular cardiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 40 citations in OpenAlex.
- Application of stem cell-derived exosomes in ischemic diseases: opportunity and limitations.Journal of translational medicine · 2021Review
- Therapeutic angiogenesis using stem cell-derived extracellular vesicles: an emerging approach for treatment of ischemic diseases.Stem cell research & therapy · 2019Review
- Implementing genome-driven personalized cardiology in clinical practice.Journal of molecular and cellular cardiology · 2018Review
- SDF1 gradient associates with the distribution of c-Kit+ cardiac cells in the heart.Scientific reports · 2018Article
- Transplantation of HGF gene-engineered skeletal myoblasts improve infarction recovery in a rat myocardial ischemia model.PloS one · 2017Article
- Stem Cell Therapy and Congenital Heart Disease.Journal of cardiovascular development and disease · 2016Review
- Is the regulation of SIRT1 by miRNA-34a the key to mesenchymal stem cell survival?Annals of translational medicine · 2016Article
- Mesenchymal Stem Cells in Cardiology.Methods in molecular biology (Clifton, N.J.) · 2016Article
- Leukemia Inhibitory Factor Enhances Endogenous Cardiomyocyte Regeneration after Myocardial Infarction.PloS one · 2016Article
- Growth hormone-releasing hormone agonists reduce myocardial infarct scar in swine with subacute ischemic cardiomyopathy.Journal of the American Heart Association · 2015Article
- New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor.Oncotarget · 2015Article
- Pathologic function and therapeutic potential of exosomes in cardiovascular disease.Biochimica et biophysica acta · 2015Review
- Stimulating endogenous cardiac repair.Frontiers in cell and developmental biology · 2015Review
- Agonists of growth hormone-releasing hormone stimulate self-renewal of cardiac stem cells and promote their survival.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Potential of cardiac stem/progenitor cells and induced pluripotent stem cells for cardiac repair in ischaemic heart disease.Clinical science (London, England : 1979) · 2013Review
- Cardiac venous arterialization in acute myocardial infarction: how great is the benefit?Interactive cardiovascular and thoracic surgery · 2013Article
- The small molecule Wnt signaling modulator ICG-001 improves contractile function in chronically infarcted rat myocardium.PloS one · 2013Article
- Key developments in stem cell therapy in cardiology.Regenerative medicine · 2012Review
- Cell-based therapy for prevention and reversal of myocardial remodeling.American journal of physiology. Heart and circulatory physiology · 2012Review
- Wnt signalling: a mediator of the heart-bone marrow axis after myocardial injury?European heart journal · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Cell-based therapy is emerging as an exciting potential therapeutic approach for cardiac regeneration following myocardial infarction (MI). As heart failure (HF) prevalence increases over time, development of new interventions designed to aid cardiac recovery from injury are crucial and should be considered more broadly. In this regard, substantial efforts to enhance the efficacy and safety of cell therapy are continuously growing along several fronts, including modifications to improve the reprogramming efficiency of inducible pluripotent stem cells (iPS), genetic engineering of adult stem cells, and administration of growth factors or small molecules to activate regenerative pathways in the injured heart. These interventions are emerging as potential therapeutic alternatives and/or adjuncts based on their potential to promote stem cell homing, proliferation, differentiation, and/or survival. Given the promise of therapeutic interventions to enhance the regenerative capacity of multipotent stem cells as well as specifically guide endogenous or exogenous stem cells into a cardiac lineage, their application in cardiac regenerative medicine should be the focus of future clinical research. This article is part of a special issue entitled "Key Signaling Molecules in Hypertrophy and Heart Failure."
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.